In other words, MET overexpression in this glioma with the G-CIMP-demethylated (C3) profile was possibly driven by the active MKLN1 promoter created by gene fusion, which led to activation of mitogen-activated protein kinase (MAPK) signaling. The gene discussed is MKLN1; the disease is glioma.